- Conditions
- Moderate to Severe Opioid-use Disorder
- Interventions
- Transmucosal Buprenorphine, Extended-release Buprenorphine
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 785 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 28
- States / cities
- Garden Grove, California • Panorama City, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 22, 2026, 12:02 AM EDT